Swedish biotech firm Orexo is ready to enter the clinical stage with a nasal candidate, OX640, for the emergency treatment of allergic reactions, which includes anaphylaxis, a company press release has announced.
Today’s first-line treatment response consists mostly of intramuscular adrenaline injections, which means the Swedish firm’s nasal candidate could be a potential challenger on the established allergy market. One firm operating there is Danish firm ALK with its rescue pen, Jext.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Demant rejects criticisms of lobbying efforts against OTC channel: "That’s how America works"
To ensure users receive a high-quality device, CEO Søren Nielsen says Demant has lobbied the FDA through a US-based industry association as it attempts to established the rules for the upcoming over-the-counter hearing aids sales channel.
Sonova downgrades, blames high costs and weak results from key markets
The hearing aid giant now expects revenue growth of 15-19% measured in local currencies, compared to a previous 17-21%.
Demant CEO highlights strong performance from Diagnostics, acknowledges Communications letdown
The Danish hearing aid manufacturer’s diagnostics business area is a beacon of light among gloomy H1 financial figures, mostly coming from headset firm Epos, says CEO Søren Nielsen.
Analyst to hone in on Vyepti rollout and patient uptake in imminent Lundbeck report
The preventive migraine treatment, Vyepti, will likely be a key element of the Danish pharmaceutical firm’s upcoming second quarterly report on Wednesday.
US downswing reflects shift in underlying demand, says Demant CEO
Demand for hearing aids on the US market will return in the future, according to Demant CEO Søren Nielsen, who thinks people are postponing the decision to acquire a device due to the challenging economic environment.
Snr. Talent Acquisition Partner, Devoteam 
Medical Scientific Communications Manager 
Experienced Biostatistician 
Vice President/Senior Director of Medicinal Chemistry 
GMP Compliance Consultant for Eltronic in Ballerup 
Sales Director, Nordic Hospital Solutions, at Mediq Denmark 
Senior Clinical Trial Manager - Black Swans Exist 
Lead Auditor – Senior Quality Assurance Specialist 
Clinical Trial Manager - Black Swans Exist 
Director Regulatory Affairs 
Senior Scientist for Analytical Development 
Clinical Biometrics Oversight Lead